Clinical Trials Directory

Trials / Completed

CompletedNCT02060890

Molecular Profiling in Guiding Individualized Treatment Plan in Adults With Recurrent/Progressive Glioblastoma

A Pilot Trial Testing the Feasibility of Using Molecular Profiling to Guide an Individualized Treatment Plan in Adults With Recurrent/Progressive Glioblastoma

Status
Completed
Phase
Study type
Observational
Enrollment
20 (actual)
Sponsor
University of California, San Francisco · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This current study will use a new treatment approach based on each patient's tumor genomic profiling consisting of whole genome sequencing, exome analysis, and RNA sequencing as well as predictive modeling. This new treatment strategy has shown promising results in adult patients with other solid tumors.

Detailed description

Patients with recurrent glioblastoma who are candidates for surgery for their clinical management will have tumor tissue taken at the time of surgery. Tissue samples will be obtained from the contrasting edge as well as infiltrating margins. Circulating tumor DNA will also be taken from blood samples before, and after surgery and every 2 months. Genomic profiling of the tumor tissue will be performed and a Molecular Tumor Board will review the profiling within 28 to 35 days of surgery. If specific potential targets are amenable to treatment, a treatment recommendation will be made. Up to 4 drugs could be suggested to the treating physician. The patient and the treating physician may or may not choose to use the recommendation. Any drug from the US Pharmacopeia may be chosen. If the treatment as suggested is given, patients will be followed for toxicity and efficacy, including progression and survival. If the treatment is not given, patients will be followed for progression and survival.

Conditions

Interventions

TypeNameDescription
OTHERspecialized tumor board recommendationfeasibility of a specialized tumor board to come up with treatment recommendations no later than 35 days from surgery.

Timeline

Start date
2014-08-01
Primary completion
2015-09-03
Completion
2017-05-10
First posted
2014-02-12
Last updated
2023-12-12
Results posted
2017-12-06

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02060890. Inclusion in this directory is not an endorsement.